Category: 1160653-94-0

On October 29, 2015, Takahashi, Taichi; Umino, Akinori; Iijima, Daisuke; Takamatsu, Hisayuki published a patent.Product Details of 1160653-94-0 The title of the patent was Novel 2-aminopyridine and 2-aminopyrimidine derivatives and medicinal use thereof. And the patent contained the following:

Provided are compounds that exhibit an excellent autotaxin (ATX) inhibitory effect, etc. and are efficacious as a prophylactic or therapeutic agent for diseases in which ATX participates. Compounds represented by general formula I [ring A = cycloalkyl, heterocyclyl, etc.; Z1-Z4 = C, N; R1 = halo, (halo)alkyl, (halo)alkoxy, aryl, etc.; R2, R3 = H, halo, (halo)alkyl, (halo)alkoxy, aryl; R4 = H, alkyl, halo; R5, R6 = H, OH, halo, etc., (linked via O, CO, etc.); L1 = bond, linear alkylene, cycloalkylene, etc] have an excellent ATX inhibitory effect and are useful as a prophylactic or therapeutic agent for ATX-associated diseases, e.g., tumor, obesity, and inflammation. The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Product Details of 1160653-94-0

The Article related to aminopyridine aminopyrimidine preparation autotaxin inhibitor antitumor antiobesity antiinflammation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Product Details of 1160653-94-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On June 4, 2020, Guillemont, Jerome Emile Georges; Lancois, David Francis Alain; Chao, Sovy; Angibaud, Patrick Rene; Mercey, Guillaume Jean Maurice; Raboisson, Pierre Jean-Marie Bernard; Michaut, Antoine Benjamin; Rigaux, Peter published a patent.Name: 3-Bromo-2-fluoro-6-methoxybenzaldehyde The title of the patent was Further heteroaromatic compounds having activity against RSV and their preparation. And the patent contained the following:

The invention concerns compounds of formula I having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment or prevention of respiratory syncytial virus infection. Compounds of formula I wherein A is substituted 1,2,3,4-tetrahydroisoquinolinyl, substituted azepanyl, amino, etc.; R5 is substituted Ph, substituted pyridinyl, substituted benzopyranyl, etc.; R15 is H and C1-4 alkyl; X1, X2 and X3 are independently N and CR; R is H and C1-4 alkyl; with provisions; and stereochem. isomeric forms thereof, are claimed. Example compound II was prepared by carboxylation of 4-(8-cyclopropyl-6-[(1R)-1-methyl-1,2,3,4-tetrahydroisoquinoline-2-carbonyl]imidazo[1,2-a]pyridin-2-yl)-3-fluorobenzoic acid. The invention compounds were evaluated for their antiviral activity. From the assay, it was determined that compound II exhibited EC50 value of 0.510μM and a CC50 value of 60.4μM. The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Name: 3-Bromo-2-fluoro-6-methoxybenzaldehyde

The Article related to heteroaromatic preparation treatment rsv infection antiviral, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Name: 3-Bromo-2-fluoro-6-methoxybenzaldehyde

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On June 18, 2015, Deligny, Michaeel Louis Robert; Heer, Jag Paul; Jackson, Victoria Elizabeth; Kroeplien, Boris; Lecomte, Fabien Claude; Porter, John Robert published a patent.Reference of 3-Bromo-2-fluoro-6-methoxybenzaldehyde The title of the patent was Imidazopyridine derivatives as modulators of TNF activity and their preparation. And the patent contained the following:

A series of substituted 3H-imidazo[4,5-b]pyridine derivatives of formula I, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurol. and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncol. disorders. Compounds of formula I wherein E is a bond, SO2 and NH and derivatives; Q is a bond, O, S, SO, SO2, etc.; Y is (un)substituted C3-7 cycloalkyl, (un)substituted aryl, (un)substituted C3-7 heterocycloalkyl, and (un)substituted heteroaryl; Z is H, halo, CF3, C1-6 alkyl, etc.; R1, R2 and R3 are independently H, halo, CN, NO2, OH, CF3, etc.; R5 is (un)substituted C1-5 alkyl; and N-oxides, pharmaceutically acceptable salts, solvates, glucuronide derivatives, and co-crystals thereof, are claimed. Example compound II was prepared by cyclocondensation of 6-chloro-N2-[(2,5-dichlorophenyl)methyl]pyridine-2,3-diamine with 2-(4-carbamoylphenoxy)acetic acid. The invention compounds were evaluated for their TNFα modulatory activity (some data given). The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Reference of 3-Bromo-2-fluoro-6-methoxybenzaldehyde

The Article related to imidazopyridine preparation tnfalpha modulator, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Reference of 3-Bromo-2-fluoro-6-methoxybenzaldehyde

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On June 23, 2022, Long, Alan; Liu, Chun Yu; Liu, Chunliang; Zhou, Yasheen; Pulley, Shon R.; Graham, Keith Andrew Newton published a patent.Product Details of 1160653-94-0 The title of the patent was Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof. And the patent contained the following:

The present invention describes novel boron containing pyrazole compounds, e.g. I, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described. The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Product Details of 1160653-94-0

The Article related to boron amidopyrazole preparation janus kinase inhibition autoimmune anticancer, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Product Details of 1160653-94-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On November 28, 2019, Takeda, Shigemitsu; Shirahase, Hiroaki; Takashima, Shunsuke; Kitao, Tatsuya published a patent.Synthetic Route of 1160653-94-0 The title of the patent was Preparation of 2H-10-oxa-2-azaanthracene-1,9-dione derivatives as readthrough inducers for premature termination codons and pharmaceutical use thereof. And the patent contained the following:

The present invention pertains to the 2H-10-oxa-2-azaanthracene-1,9-dione compounds (1,2-dihydro-10H-pyrido[4,3-b]chromene-1,10-dione derivatives) represented by general formula I [R1 = (un)substituted ring group; R2 = each (un)substituted C1-6 alkyl, C3-6 cycloalkyl, or C3-8 cycloalkenyl; R3, R4, R5 = each independently H, halo, cyano, hydroxy, or each (un)substituted acyl, NH2, C1-6 alkyl, C1-6 alkoxy, heterocyclyl, or heterocyclyloxy; or R3 and R4 or R4 and R5 are bonded to each other to form each (un)substituted C5-7 cycloalkene or 5- to 7-membered monocyclic nonaromatic heterocyclic ring together with the carbon atoms to which they are bonded]. A pharmaceutical composition containing the compound I or its pharmaceutically acceptable salt as an active ingredient, a readthrough inducer for premature termination codons containing the compound I or its pharmaceutically acceptable salt, and a prophylactic or therapeutic agent containing the compound I or its pharmaceutically acceptable salt as an active ingredient for nonsense mutation genetic disorder are also provided. The nonsense mutation genetic disorder is mucopolysaccharidosis, muscular dystrophy, Duchenne muscular dystrophy, cystic fibrosis, ceroid lipofuscinosis or Niemann-Pick disease. The compounds I or pharmaceutically acceptable salt thereof have readthrough activity for the nonsense mutation that results in premature termination codons, enable the production of full-length proteins, and are useful for the prevention or treatment of the nonsense mutation genetic disorder described above. Thus, 6-cyclobutyl-2-oxo-1-phenyl-1,2-dihydropyridin-4-yl 2-fluorobenzoate was esterified by 2-fluorobenzoyl chloride in the presence of Et3N in toluene at room temperature fro 40 min to quant. give 6-cyclobutyl-2-oxo-1-phenyl-1,2-dihydropyridin-4-yl 2-fluorobenzoate which underwent cyclization by treatment with KCN, Et3N, and 18-crown-6 in toluene at 50° for 4 h to give 43% 3-cyclobutyl-2-phenyl-2H-10-oxa-2-azaanthracene-1,9-dione (II). II at 3 μM increased the activity of α-L-iduronidase 1.5 to -10-times in Hurler syndrome patient-derived fibroblast possessing α-L-iduronidase W402X-mutation. The experimental process involved the reaction of 3-Bromo-2-fluoro-6-methoxybenzaldehyde(cas: 1160653-94-0).Synthetic Route of 1160653-94-0

The Article related to nonsense mutation genetic disorder prevention treatment oxaazaanthracenedione preparation, dihydropyridochromenedione oxaazaanthracenedione preparation readthrough inducer premature termination codon, mucopolysaccharidosis muscular dystrophy prevention treatment, duchenne muscular dystrophy cystic fibrosis prevention treatment and other aspects.Synthetic Route of 1160653-94-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary